This is a routine IP update with no hard catalysts. Monitor for clinical trial results or regulatory filings that could move the stock. Given the $2M market cap and historical volatility, any news could cause outsized moves, but this specific announcement lacks materiality.
Price Chart
Executive Summary
Clearmind Medicine announced a Japanese patent application for its MEAI-based depression treatment, expanding its IP portfolio. The press release contains no financial data or clinical results, only forward-looking statements about market growth and pipeline expansion.
Key Facts
- Filed a Japanese patent application for MEAI compositions to treat depression
- MEAI is a non-hallucinogenic neuroplastogen molecule
- Company has 19 patent families and 31 granted patents globally
- No financial data, clinical trial results, or regulatory milestones disclosed
- Market cap is approximately $2M
Financial Impact
No financial figures disclosed; patent application is a procedural IP step with no immediate revenue impact
Risk Factors
- No guarantee the Japanese patent will be granted
- Company is pre-revenue clinical-stage with no approved products
- Forward-looking statements about market growth are speculative
- Low market cap ($2M) increases susceptibility to dilution or delisting risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303585 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $6.12 (+3.40%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $6.12 (−5.83%) |
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers